Literature DB >> 21930187

Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Jonathan D Wasserman1, Gerard P Zambetti, David Malkin.   

Abstract

Adrenocortical carcinoma (ACC) is recognized to be a component tumor of the Li Fraumeni Syndrome (LFS), a familial cancer predisposition resulting from germline mutations in the p53 tumor-suppressor. p53 activity is tightly regulated by multiple post-translational mechanisms, disruption of which may lead to tumorigenesis. ACC is present in disproportionately high rates among p53-mutation carriers, suggesting tissue-specific manifestations of p53 deficiency. Additionally, p53-associated ACC demonstrates a strong predominance in infants and children. Several of the p53 alleles associated with pediatric ACC, however, retain significant wild-type activity and demonstrate incomplete penetrance, a finding distinct from other LFS-component tumors. In this review, we discuss the relationship between p53 and adrenocortical carcinogenesis, with specific focus on disease-specific alleles, tumorigenesis in the context of adrenal development and potential therapeutic approaches to p53-associated ACC. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21930187      PMCID: PMC3288384          DOI: 10.1016/j.mce.2011.09.010

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  129 in total

Review 1.  p53 and human cancer: the first ten thousand mutations.

Authors:  P Hainaut; M Hollstein
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

2.  Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription.

Authors:  Shuichi Ohkubo; Tomoaki Tanaka; Yoichi Taya; Kenji Kitazato; Carol Prives
Journal:  J Biol Chem       Date:  2006-04-19       Impact factor: 5.157

3.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

Authors:  Ke Ding; Yipin Lu; Zaneta Nikolovska-Coleska; Guoping Wang; Su Qiu; Sanjeev Shangary; Wei Gao; Dongguang Qin; Jeanne Stuckey; Krzysztof Krajewski; Peter P Roller; Shaomeng Wang
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

4.  Modeling the therapeutic efficacy of p53 restoration in tumors.

Authors:  Carla P Martins; Lamorna Brown-Swigart; Gerard I Evan
Journal:  Cell       Date:  2006-12-21       Impact factor: 41.582

5.  The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.

Authors:  Mariëlle W G Ruijs; Marjanka K Schmidt; Heli Nevanlinna; Johanna Tommiska; Kristiina Aittomäki; Roelof Pruntel; Senno Verhoef; Laura J Van't Veer
Journal:  Eur J Hum Genet       Date:  2006-09-27       Impact factor: 4.246

6.  Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.

Authors:  Lawrence R Dearth; Hua Qian; Ting Wang; Timothy E Baroni; Jue Zeng; Stephanie W Chen; Sun Young Yi; Rainer K Brachmann
Journal:  Carcinogenesis       Date:  2006-07-21       Impact factor: 4.944

7.  Gene expression profiling of childhood adrenocortical tumors.

Authors:  Alina Nico West; Geoffrey A Neale; Stanley Pounds; Bonald C Figueredo; Carlos Rodriguez Galindo; Mara Albonei D Pianovski; Antonio G Oliveira Filho; David Malkin; Enzo Lalli; Raul Ribeiro; Gerard P Zambetti
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

8.  The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.

Authors:  Maria Isabel Waddington Achatz; Magali Olivier; Florence Le Calvez; Ghyslaine Martel-Planche; Ademar Lopes; Benedito Mauro Rossi; Patricia Ashton-Prolla; Roberto Giugliani; Edenir Inez Palmero; Fernando Regla Vargas; José Claudio Casali Da Rocha; Andre Luiz Vettore; Pierre Hainaut
Journal:  Cancer Lett       Date:  2006-02-21       Impact factor: 8.679

Review 9.  Massively regulated genes: the example of TP53.

Authors:  Monica Hollstein; Pierre Hainaut
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

10.  Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis.

Authors:  B Cecchinelli; A Porrello; C Lazzari; A Gradi; G Bossi; M D'Angelo; A Sacchi; S Soddu
Journal:  Cell Death Differ       Date:  2006-05-26       Impact factor: 15.828

View more
  26 in total

1.  Metastatic Adrenocortical Carcinoma: a Single Institutional Experience.

Authors:  Dwight H Owen; Sandipkumar Patel; Lai Wei; John E Phay; Lawrence A Shirley; Lawrence S Kirschner; Carl Schmidt; Sherif Abdel-Misih; Pamela Brock; Manisha H Shah; Bhavana Konda
Journal:  Horm Cancer       Date:  2019-08-29       Impact factor: 3.869

Review 2.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

3.  Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.

Authors:  Jonathan D Wasserman; Ana Novokmet; Claudia Eichler-Jonsson; Raul C Ribeiro; Carlos Rodriguez-Galindo; Gerard P Zambetti; David Malkin
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

4.  Usefulness of Wieneke criteria in assessing morphologic characteristics of adrenocortical tumors in children.

Authors:  Gaurav Chatterjee; Shatavisha DasGupta; Gautam Mukherjee; Moumita Sengupta; Paromita Roy; Indu Arun; Chhanda Datta; Prafulla Kumar Mishra; Sugato Banerjee; Uttara Chatterjee
Journal:  Pediatr Surg Int       Date:  2015-04-17       Impact factor: 1.827

Review 5.  Adrenocortical tumorigenesis: Lessons from genetics.

Authors:  Crystal D C Kamilaris; Fady Hannah-Shmouni; Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2020-05-23       Impact factor: 4.690

6.  The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.

Authors:  Shelley Macaulay; Quintin Clive Goodyear; Mia Kruger; Wenlong Chen; Fahmida Essop; Amanda Krause
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

7.  Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors.

Authors:  Gislaine Custódio; Guilherme A Parise; Nilton Kiesel Filho; Heloisa Komechen; Cesar C Sabbaga; Roberto Rosati; Leila Grisa; Ivy Z S Parise; Mara A D Pianovski; Carmem M C M Fiori; Jorge A Ledesma; José Renato S Barbosa; Francisco R O Figueiredo; Elis R Sade; Humberto Ibañez; Sohaila B I Arram; Sérvio T Stinghen; Luciano R Mengarelli; Mirna M O Figueiredo; Danilo C Carvalho; Sylvio G A Avilla; Thiago D Woiski; Lisiane C Poncio; Geneci F R Lima; Roberto Pontarolo; Enzo Lalli; Yinmei Zhou; Gerard P Zambetti; Raul C Ribeiro; Bonald C Figueiredo
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

Review 8.  Mouse models of adrenocortical tumors.

Authors:  Kaitlin J Basham; Holly A Hung; Antonio M Lerario; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2015-12-08       Impact factor: 4.102

Review 9.  5th International ACC Symposium: Hereditary Predisposition to Childhood ACC and the Associated Molecular Phenotype: 5th International ACC Symposium Session: Not Just for Kids!

Authors:  Tobias Else; Carlos Rodriguez-Galindo
Journal:  Horm Cancer       Date:  2015-12-10       Impact factor: 3.869

10.  Adrenocortical Carcinoma Steroid Profiles: In Silico Pan-Cancer Analysis of TCGA Data Uncovers Immunotherapy Targets for Potential Improved Outcomes.

Authors:  João C D Muzzi; Jessica M Magno; Milena A Cardoso; Juliana de Moura; Mauro A A Castro; Bonald C Figueiredo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-14       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.